

2017



Progetto Ematologia Romagna

La Coagulazione Intravascolare Disseminata
Inquadramento del problema

Marco Marietta - Modena



Relazioni con soggetti portatori di interessi commerciali in campo sanitario

Ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 17 del Regolamento Applicativo dell'Accordo Stato-Regione del 5 novembre 2009, io sottoscritto **Dott. Marco Marietta** dichiaro che negli ultimi due anni ho avuto i seguenti rapporti ricevendo compensi individuali con soggetti portatori di interessi commerciali in campo sanitario:

Partecipazione ad Advisory Board per l' Azienda Novo-Nordisk

Relazioni a congressi per la ditta Kedrion, Orphan, Novo-Nordisk, Werfen



2017



PROGETTO EMATOLOGIA – ROMAGNA Rimini, 8 aprile 2017



*«Se vi è l'impronta dev'esserci stato qualcosa di cui è l'impronta».
«Ma diverso dall'impronta, mi dite».
«Certo. Non sempre un'impronta ha la forma del corpo che l'ha
impressa e non sempre nasce dalla pressione di un corpo.
Talora [...] è l'impronta di un'idea.
L'idea è segno delle cose, e l'immagine è segno dell'idea, segno di
un segno.*

*Ma dall'immagine ricostruisco, se non il corpo, l'idea che altri ne
aveva».*

Umberto Eco. Il nome della rosa



L'immagine è segno dell'idea, segno di un segno...

- ✓ Plt 98.000/mmc
- ✓ PT INR 1.4
- ✓ Fibrinogeno 182 mg/dl
- ✓ D-dimero 11280 ng/ml

Table 1 Scoring system for overt Disseminated Intravascular Coagulation (DIC)

1. Risk assessment: does the patient have an underlying disorder known to be associated with overt DIC?

If yes: Proceed.

If no: Do not use this algorithm.

2. Order global coagulation tests (platelet count, prothrombin time, fibrinogen, fibrin-related marker).

3. Score global coagulation test results.

- Platelet count
($>100 = 0$; $<100 = 1$; $<50 = 2$)
- Elevated fibrin related marker (e.g. D-dimers; fibrin degradation products)
(no increase = 0; moderate increase = 2; strong increase = 3)
- Prolonged prothrombin time
($<3\text{ s} = 0$; $>3\text{ but } <6\text{ s} = 1$; $>6\text{ s} = 2$)
- Fibrinogen level
($>1.0\text{gL}^{-1} = 0$; $<1.0\text{gL}^{-1} = 1$)

1

3

1

0

5. Calculate score

If ≥ 5 : compatible with overt DIC: repeat score daily

If < 5 : suggestive (not affirmative) for non-overt DIC: repeat next 1–2 days.



L'immagine è segno dell'idea, segno di un segno...

LA PROMIELOCITICA

TRAUMA


- ✓ Plt 98.000/mmc
- ✓ PT INR 1.4
- ✓ Fibrinogeno 182 mg/dl
- ✓ D-dimero 11280 ng/ml

SEPSI

Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines

H. WADA,* J. THACHIL,† M. DI NISIO,‡§ P. MATHEW,¶ S. KUROSAWA,** S. GANDO,†† H.K. KIM,‡‡ J.D. NIELSEN,§§ C-E. DEMPFLER,¶¶ M. LEVI,§ C-H. TOH***††† and THE SCIENTIFIC AND STANDARDIZATION COMMITTEE ON DIC OF THE ISTH

- ✓ Disseminated intravascular coagulation (DIC) is a syndrome characterized by the systemic activation of blood coagulation, which generates intravascular fibrin, leading to thrombosis of small and medium-sized vessels, and eventually organ dysfunction.
- ✓ DIC may occur as a complication of infections, solid cancers, hematologic malignancies, obstetric diseases, trauma, aneurysm, and liver diseases
- ✓ ***Each type of DIC presents characteristic features related to the underlying disorder.***



Thro	Thrombin functions in coagulation	
Focus: Jolanta	Procoagulant properties	<ul style="list-style-type: none"> ● cleavage of fibrinogen and liberation of fibrinopeptide A and B (10) ● activation of factors: V (128), VIII (129), XI (130) and XIII (131) ● induction of platelet aggregation, platelet secretion and platelet procoagulant activity (132) ● release of adenosine diphosphate from platelets (132) ● expression of P-selectin on endothelial cells (133, 134) ● stimulation of expression of the platelet activating factor (PAF)
	Antifibrinolytic properties	<ul style="list-style-type: none"> ● activation of thrombin-activable fibrinolysis inhibitor (TAFI) (136) ● release of the plasminogen activator inhibitor-1 (137)

Thrombin as a multi-functional enzyme

Focus on *in vitro* and *in vivo* effects

Jolanta M. Siller-Matula¹; Michael Schwameis²; Andrew Blann³; Christine Mannhalter⁴; Bernd Jilma²

Anticoagulant properties

- binding to thrombomodulin (TM) and activation of protein C
- decrease in the binding of von Willebrand factor (vWF) to glycoprotein (GP) Ib (135)
- decrease in ristocetin-induced agglutination (135)

Fibrinolytic properties


- release of the tissue plasminogen activator (138)

Coagulation and non-coagulation effects of thrombin

J. J. N. POSMA, J. J. POSTHUMA and H. M. H. SPRONK

- ✓ Thrombin mainly regulates cellular responses through activation of **PARs**, but can have opposite effects on the same cell, depending on various conditions, such as the concentration, the location, the exposure time, and the presence of cofactors .
- ✓ Through activation of PARs, thrombin can regulate physiologic processes such as embryonic development and wound healing, but also pathophysiologic processes such as **sepsis, cancer, fibrosis, and inflammation**.
- ✓ Activation of PARs by thrombin can lead to **2224 different intracellular phosphorylations in the cell**, making investigation of the various effects of thrombin on cellular pathways challenging

Coagulation and non-coagulation effects of thrombin



Bleeding related to disturbed fibrinolysis

Krasimir Kolev¹ and Colin Longstaff²

- ✓ DIC is a common severe complication of systemic infection (sepsis) and extensive tissue destruction (major trauma).
- ✓ DIC is defined as *‘an acquired syndrome characterized by the intravascular activation of coagulation with loss of localization arising from different causes. It can originate from and cause damage to the microvasculature, which if sufficiently severe, can produce organ dysfunction’* (ISTH, 2001).
- ✓ *Depending on the nature of the provoking factor and the stage of the disease, the phenotype of DIC can be either thrombotic or haemorrhagic.*



Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype

Mineji Hayakawa

Table 1 Characteristics of DIC phenotypes

	Fibrinolytic phenotype	Thrombotic phenotype
--	------------------------	----------------------



Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype

Mineji Hayakawa

Table 1 Characteristics of DIC phenotypes

	Fibrinolytic phenotype	Thrombotic phenotype
Representative cause	Acute promyelocitic leukemia	Sepsis
Coagulation	Activated	Activated
Fibrinolysis	Activated	Suppressed
PAI-1	Low	High
Clinical symptom	Bleeding	Organ dysfunction

DIC disseminated intravascular coagulation, *PAI* plasminogen activator inhibitor

- ✓ Acute promyelocytic leukaemia (APL) is characterized by a high rate of life-threatening haemorrhagic events related to hyperfibrinolysis.
- ✓ **Low TAFI activity** has been reported in APL patients probably due to excessive inactivation of TAFI by plasmin
- ✓ PML-RAR- α enhances the expression of S100A10 (p11), a member of the S100 family of calcium-binding proteins which forms a heterotetrameric (S100A10) $_2$ -(annexin A2) $_2$ complex on the surface of various cells
- ✓ **The (S100A10) $_2$ -(annexin A2) $_2$ complex provides a template for plasminogen activation on the cell surface** and protects plasmin against plasma inhibitors in a similar way to fibrin.
- ✓ These S100A10-related pro-fibrinolytic effects are consistent with the bleeding profile in APL

Kolev K, BJH 2016



2017

The Coagulopathy of Acute promyelocytic leukaemia

- ✓ ATRA treatment reverses the S100A10 and annexin A2 induction in PML-RAR-a positive cells and suppresses plasmin generation on their surface
- ✓ An additional factor for the profibrinolytic state in APL could be the release of **neutrophil elastase** from the leukaemic promyelocytes
- ✓ The evidence justifies the classification of the haemostatic imbalance in APL as **primary hyperfibrinolysis**, and this conclusion is supported by the typical laboratory findings in the blood of APL patients

Kolev K, BJH 2016




Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype

Mineji Hayakawa

Table 1 Characteristics of DIC phenotypes

	Fibrinolytic phenotype	Thrombotic phenotype
Representative cause	Acute phase of trauma	Sepsis
Coagulation	Activated	Activated
Fibrinolysis	Activated	Suppressed
PAI-1	Low	High
Clinical symptom	Bleeding	Organ dysfunction

DIC disseminated intravascular coagulation, *PAI* plasminogen activator inhibitor




Thorsen K et al. Br J Surg 2011;98:894-907



Pathophysiology of trauma-associated coagulopathy


Mineji Hayakawa



Acute traumatic coagulopathy: pathophysiology and resuscitation

British Journal of Anaesthesia, 117 (S3): iii31–iii43 (2016)

J. W. Simmons* and M. F. Powell





Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype


Mineji Hayakawa


Table 1 Characteristics of DIC phenotypes

	Fibrinolytic phenotype	Thrombotic phenotype
Representative cause	Acute phase of trauma	Sepsis
Coagulation	Activated	Activated
Fibrinolysis	Activated	Suppressed
PAI-1	Low	High
Clinical symptom	Bleeding	Organ dysfunction

DIC disseminated intravascular coagulation, *PAI* plasminogen activator inhibitor

Innate immune cells have evolved cell-specific prothrombotic pathways that operate in intact blood vessels to protect hosts from non-self and altered-self.







The microvascular accretion and deposition of fibrinogen on the surface of endothelial cells leads to the recruitment of additional cells to the site of tissue injury and damage, further supporting the recognition of pathogens and coordination of immune response. This process is supported by innate immune cells and antimicrobial peptides that are released during the activation of the immune system and/or released by activated cells to facilitate pathogen immobilization.

IT prevents tissue invasion by pathogens through the formation of microthrombi in microvessels.

Immunothrombosis helps to capture and ensnare pathogens circulating in the blood and thereby limits pathogen dissemination by retaining the microorganisms within the fibrin network.




NETs consist of a framework of filamentous DNA (chromatin) adorned with histone proteins and several antibacterial components, including elastase, that are expelled from activated neutrophils.



NETs can directly activate factor XII (the contact pathway of coagulation). They bind to von Willebrand factor (VWF) and support the recruitment of platelets. Histones H3 and H4 can trigger the activation of platelets. NETs locally concentrate enzymes, such as neutrophil elastase and myeloperoxidase, which respectively cleave and oxidize anticoagulants, including TFPI and thrombomodulin. Such inactivation of endogenous anticoagulants propagates coagulation. And finally, NETs can bind to tissue factor and promote the activation of the extrinsic pathway of coagulation.

involved cell-specific prothrombotic pathways that to protect hosts from non-self and altered-self.



The complement system (specifically the activated complement components C3a and C5a) also supports immunothrombosis, for example by triggering platelet activation.



ELSEVIER

Thrombosis Research 151, Suppl. 1 (2017) S56–S60

Thrombosis Research

journal homepage: www.elsevier.com/locate/thromres



The clinical presentation of DIC may be the results of the following mechanisms.

✓ ***Endothelial dysfunction and platelet activation*** In HELLP syndrome, a systemic inflammatory response is associated with markedly increased circulating pro-inflammatory cytokines such as TNF- α , IL-1 and IL-6 which can lead to expression of TF by leukocyte and endothelial cells

✓ ***Trophoblast properties and activation of the coagulation system***

The trophoblast is both

- ***anticoagulant***: in the intervillous space by expression of anticoagulation proteins;
- ***procoagulant***: at the maternal fetal interface by expression of placental TF

In any condition that disrupts the integrity of the trophoblast such as placental abruption and amniotic fluid embolism large amount of TF are released.



ELSEVIER

Thrombosis Research 151, Suppl. 1 (2017) S56–S60

Thrombosis Research

journal homepage: www.elsevier.com/locate/thromres



✓ ***Impaired liver function***

In **HELLP syndrome** or in **acute fatty liver of pregnancy** the injury to the liver leads to a reduction in the production of anticoagulation proteins and coagulation factors leading to increase susceptibility of the mother to both hemorrhage and thrombosis.

✓ **Post-partum hemorrhage.**

Obstetrical complications causing PPH are: **uterine atony, retained placenta or membranes, uterine rupture, placenta accreta, or severe cervical or vaginal lacerations.** The loss of large amount of coagulation factors and natural inhibitors of coagulation can worsen bleeding leading to a consumption coagulopathy and to an overt DIC, which in turn worsens the bleeding



ELSEVIER



Table 1

Comparison among the pregnancy modified DIC score by Erez et al. and the other DIC scores in current clinical use.

Parameters	ISTH score	Pregnancy Modified ISTH score	
		Erez et al. [2]	Clark et al. [51]
Platelet count ($10^9/L$)	>100 = 0 <100 = 1 <50 = 2	>185 = 0 100–185 = 1 50–100 = 2 <50 = 1	>100 = 0 50–100 = 1 <50 = 2
Fibrin-related markers (e.g. soluble fibrin monomers/ fibrin degradation products)	no increase: 0 moderate increase: 2 strong increase: 3		
Prothrombin time (value of patient/normal value)	<3 s = 0 ≥ 3 s but <6 s = 1 ≥ 6 s = 2	<0.5 = 0 0.5–1 = 5 1.0–1.5 = 12 >1.5 = 25	<25% increase = 0 25–50% increase = 1 >50% increase = 2
Fibrinogen level (g/L)	<1.0 = 1 >1.0 = 0	3.0 = 25 3.0–4.0 = 6 4.0–4.5 = 1 >4.5 = 0	<2.0 = 1 >2.0 = 0
Calculated score	>5: compatible with overt DIC; repeat scoring daily <5: suggestive (not affirmative) for non-overt DIC; repeat next 1–2 days	>26 high probability for DIC	>3 compatible with overt DIC in pregnancy

ISTH, International Society for Thrombosis and Haemostasis; JAAM, Japanese Association for Acute Medicine; SIRS, systemic inflammatory response syndrome.


2017



« *Dubium sapientiae initium* »
René Descartes, *Meditationes de prima philosophia*


Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia

Eduard J. Libourel,^{1,2} Clara P. W. Klerk,³ Yvette van Norden,⁴ Moniek P. M. de Maat,² Marieke J. Kruip,² Pieter Sonneveld,² Bob Löwenberg,² and Frank W. G. Leebeek²



Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia

Eduard J. Libourel,^{1,2} Clara P. W. Klerk,³ Yvette van Norden,⁴ Moniek P. M. de Maat,² Marieke J. Kruip,² Pieter Sonneveld,² Bob Löwenberg,² and Frank W. G. Leebeek²





Dalla fisiopatologia alla clinica...

- ✓ DIC con fenotipo iperfibrinolitico → antifibrinolitici?
- ✓ DIC con fenotipo protrombotico → anticoagulanti naturali?



2017

Dalla fisiopatologia alla clinica...




PROGETTO EMATOLOGIA – ROMAGNA

Rimini, 8 aprile 2017



2017



PROGETTO EMATOLOGIA – ROMAGNA Rimini, 8 aprile 2017



«Voglio dirti solo una parola, ragazzo. Solo una parola»
«Sì, signore». «Mi ascolti?». «Sì, signore».



«*Trombina*». Pausa. «Credo di non avere capito, signore».
«*Trombina*, Ben. Il futuro è nella *trombina*»

Il Laureato – 1967

- Bacterial invasion prompts a compelling upregulation of the coagulation system and inhibits anticoagulant and fibrinolytic pathways, which results in widespread microvascular fibrin deposition
- Dual inhibition of activated FII and activated FX (SATI) diminishes thrombin formation and preserves anticoagulant and fibrinolytic pathways
- SATI administration strongly ameliorates IL-6 release in severe sepsis
- SATI robustly attenuates sepsis-induced organ damage and protects organ function